Medication info
Trevel 40/5/5 mg Tablet

Trevel 40/5/5 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201802586 · Approved 2018.06.20 · Insurance code 693902860

Summary

Main use
Treatment of hypertension and dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single agent, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased by approximately 2.4-fold and AUC by approximately 1.3-fold. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed and patients should be monitored closely.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels.
View approved original text

This medication is specifically used for patients with essential hypertension whose blood pressure is not adequately controlled with telmisartan and amlodipine combination therapy, and for patients with hyperlipidemia who require rosuvastatin calcium. The telmisartan/amlodipine combination helps to effectively control blood pressure. Rosuvastatin is used for patients with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia that are not controlled by diet and exercise. It also contributes to lowering total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and reducing the risk of cardiovascular disease. Especially in high-risk patients, there is a risk reduction effect for stroke, myocardial infarction, and coronary revascularization. Therefore, this medication effectively improves hypertension and hyperlipidemia.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single agent, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual ingredients (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased up to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased by approximately 2.4-fold and AUC by approximately 1.3-fold. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed and patients should be monitored closely.

Precautions

This medication can cause serious harm or death to the fetus and newborn if administered to a pregnant woman; therefore, it should be stopped immediately upon confirmation of pregnancy. Patients with allergic reactions to any component of this medication, certain hereditary diseases, severe liver or kidney diseases, or severe heart diseases should not take this medication. Elderly patients or patients with very low blood pressure, diminished liver or kidney function, or high potassium levels in the blood should use this medication with caution. Muscle pain, muscle weakness, and in severe cases, muscle destruction and kidney damage can occur while taking this medication, so if muscle pain or weakness occurs, you should consult a doctor immediately. Liver function abnormalities may occur, so regular liver function tests before and during medication are important. This medication can interact with various other drugs, so if you are currently taking any other medications, you must inform your doctor or pharmacist. Women who may become pregnant must use appropriate contraception, and those who are breastfeeding should avoid taking it or discontinue breastfeeding. Overdose may cause hypotension, dizziness, arrhythmias, etc.; if these symptoms occur, you need to seek medical help immediately. It is not recommended for children as safety and efficacy are not adequately established, and the elderly should take it with caution, adjusting the dosage accordingly. When storing this medication, it should be kept out of the reach of children and not transferred to another container.

Side effects

  • Viral upper respiratory tract infection
  • dyspnea
  • hemorrhoidal bleeding
  • dyspepsia
  • atopic dermatitis
  • peripheral edema
  • chronic gastritis
  • various gastrointestinal disorders
  • hiatal hernia
  • dysuria
Show 150 more
  • rhinitis
  • oropharyngeal discomfort
  • lung disease
  • unspecified intestinal disorder
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory impairment
  • movement disorders
  • frequent urination
  • tinnitus
  • hearing loss
  • halitosis
  • fatty liver
  • headache
  • dizziness
  • orthostatic hypotension
  • low back pain
  • edema
  • flushing
  • palpitations
  • fatigue
  • drowsiness
  • arrhythmia
  • bradycardia
  • chest pain
  • peripheral ischemia
  • syncope
  • vasculitis
  • peripheral neuropathy
  • tremor
  • loss of appetite
  • constipation
  • dysphagia
  • pancreatitis
  • vomiting
  • gingival hyperplasia
  • allergic reaction
  • low back pain
  • burning sensation
  • lethargy
  • pain
  • stiffness
  • weight gain
  • weight loss
  • arthralgia
  • arthritis
  • muscle cramps
  • myalgia
  • erectile dysfunction
  • insomnia
  • neuralgia
  • depression
  • abnormal dreams
  • anxiety
  • dissociation
  • dyspnea
  • epistaxis
  • angioedema
  • erythema multiforme
  • pruritus
  • rash
  • erythematous rash
  • papular rash
  • visual disturbances
  • conjunctivitis
  • diplopia
  • ocular pain
  • tinnitus
  • ear pain
  • frequent urination
  • voiding dysfunction
  • nocturia
  • dry mouth
  • increased sweating
  • hyperglycemia
  • thirst
  • leukopenia
  • purpura
  • thrombocytopenia
  • headache
  • weakness
  • cough
  • asthenia
  • facial edema
  • lower limb edema
  • angioedema
  • pruritus
  • hypersensitivity reaction
  • increased sweating
  • erythema
  • chest pain
  • atrial fibrillation
  • congestive heart failure
  • myocardial infarction
  • elevated blood pressure
  • worsening hypertension
  • hypotension
  • hyperkalemia
  • hypoglycemia
  • syncope
  • dyspepsia
  • diarrhea
  • pain
  • urinary tract infection
  • erectile dysfunction
  • abdominal pain
  • muscle cramps
  • bradycardia
  • eosinophilia
  • thrombocytopenia
  • increased uric acid
  • abnormal liver function
  • liver disease
  • acute kidney failure
  • anemia
  • elevated CPK
  • anaphylactic reaction
  • tendon pain
  • angioedema
  • headache
  • dizziness
  • constipation
  • nausea
  • abdominal pain
  • pancreatitis
  • pruritus
  • rash
  • urticaria
  • myalgia
  • myopathy
  • rhabdomyolysis
  • weakness
  • dysuria
  • rhinitis
  • oropharyngeal discomfort
  • lung disease
  • unspecified intestinal disorder
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory impairment
  • movement disorders
  • frequent urination
  • tinnitus
  • hearing loss
  • halitosis
  • fatty liver

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a special container to protect it from light and air, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. This is to maintain the efficacy of the medication and prevent degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.